Merck Enters Global Licensing Agreement With SciBrunch Therapeutics
Merck (MRK) has signed an exclusive global licensing agreement with SciBrunch Therapeutics to develop and commercialize SPR2015, an investigational oral KRAS G12D inhibitor. The deal includes a $400 million upfront payment from Merck to SciBrunch. SciBrunch retains the right to receive additional payments tied to development milestones and potential future sales of the drug candidate. This partnership allows Merck access to SPR2015, which is in early-stage research for treating certain cancers driven by KRAS mutations—a historically difficult target in oncology. The agreement highlights ongoing efforts among pharmaceutical companies to advance innovative cancer therapies targeting previously undruggable proteins like KRAS.
Tickers: $MRK
Topics: drug development KRAS G12D inhibitor licensing agreement